---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-284564"
form_type: "8-K"
ticker: "ABOS"
cik: "0001576885"
company_name: "Acumen Pharmaceuticals, Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T20:10:13.426331+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Acumen Q3 net loss $10.7M; INTERCEPT-AD Phase 1 on track, FDA Fast Track granted

## Summary
- Cash, equivalents & marketable securities $200.2M at Sep 30, 2022, sufficient through 2025.
- R&D expenses $8.3M (Q3 2022) vs $1.8M (Q3 2021) due to clinical trial ramp.
- INTERCEPT-AD enrollment expected to complete Q1 2023; topline data anticipated H2 2023.
- FDA granted Fast Track designation for ACU193 in early Alzheimer's in October 2022.
- Appointed Derek Meisner as Chief Legal Officer in September 2022.

## SEC filing metadata
- accession: 0001193125-22-284564
- form_type: 8-K
- ticker: ABOS
- cik: 0001576885
- company_name: Acumen Pharmaceuticals, Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576885/000119312522284564/0001193125-22-284564-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576885/000119312522284564/d410427d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-284564
- JSON: https://secwatch.observer/filing/0001193125-22-284564.json
- Plain text: https://secwatch.observer/filing/0001193125-22-284564.txt

## Key facts
- Earnings Releases
  Acumen Pharmaceuticals, Inc. reported the quarter ended September 30, 2022 results: net income $10.7 million.
  - Period: the quarter ended September 30, 2022
  - Net income: $10.7 million
  - Result: reported results
  source text: Net loss was $10.7 million for the three-month period ended September 30, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576885/000119312522284564/0001193125-22-284564-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.